Rethinking sales to identify, promote and prove real value

 

Product Launch

Support your global expansion with a strong local infrastructure

• Boost sales in new therapeutic areas with highly experienced specialty sales teams.
• Rapidly expand into one or several new geographic areas.
• Maintain continuity of territory coverage with a zero vacancy sales team.
• Deploy a sales force supplemented with remote engagement.

Sales and Marketing Services 

Product Launch
A proven tactic to accomplishing commercial success
Preserve your brand with Local knowledge
Determining the best approach to launch can be challenging in Iran market. Out licensing may provide immediate commercial muscle at the expense of autonomy, but building the commercial infrastructure to independently support a successful launch may drain capital needed elsewhere. You need a partner with a deep understanding of diverse stakeholders in Iran market, new health systems and pharma branding, and the resources to implement smart strategies.

The right resources at every step
ExirHealth has supported more than 35 product launches in Iran since 2009. Guided by MNC priorities, we help MNC drive successful commercialization with a complete lineup of services. From upfront strategic planning to tactical execution, we can accurately assess the gaps in your capabilities, then rapidly fill them with highly skilled marketers, medics, regulatory experts and sales leaders.

Benefits of a commercialization partnership with ESS include:

• Retaining full strategic control over your product.
• Keeping internal resources focused on your core portfolio.
• Maximizing the value of your product to your company.
• Retaining the flexibility for future business opportunities.
• Reduced operational risk.

Finding partners in an evolving marketplace
Maintaining status quo within sales operations isn’t an option if you want to stay ahead of your competitors. Sales models must be attuned to market trends, and teams must be flexible and responsive to a dynamic marketplace. All the necessary resources may not be in-house, but in order to realize maximum efficiencies perhaps they shouldn’t be.

Tailoring teams to your goals
With 8 years of experience, 35 brand launches, more than 50 specialty and primary care sales representatives in 20 Provinces, and customer satisfaction scores that consistently exceed 90%, ExirHealth knows how to build winning teams. In addition to recruiting, training and managing your sales force, our pharmaceutical sales solutions go far beyond those of traditional sales organizations, including:
•    Boost sales in new therapeutic areas with highly experienced specialty sales teams.
•    Rapidly expand into one or several  geographic areas.
•    Maintain continuity of territory coverage with a zero vacancy sales team.
•    Deploy a sales force supplemented with remote engagement.

Integrated Channel Management
A connected engagement strategy to reach physicians the right way
Getting your product message in front of physicians has become more interesting. Restrictions in the number of sales rep visits to healthcare providers (HCPs), Higher number of patients to see, and an increased amount of information through a variety of digital channels, it is getting harder every day for your message to reach HCPs effectively. Relying only on traditional face-to-face interaction through sales representatives won’t show the returns that could be achieved through a multichannel approach

Connect results to improve your probability of success
Choosing the right channel mix and understanding the impact of your activities requires you to:

• Understand  your Iranian target audiences preferred communication channels
• Connect the various channels to track results and make more informed decisions 
• Employ a good balance between non-personal, personal, live communication
• Be flexible - adjust the channel mix, according to context
• Ensure consistency of message through different channels while keeping content fresh

An integrated multichannel engagement solution with ExirHealth allows you to:

• Tap into our deep understanding of healthcare systems and stakeholders
• Use our ability to reach stakeholders and identify the channels that resonate best with them
• Leverage our capabilities in designing, executing and measuring your multi-channel program
• Rely on us to provide a solution that is compliant with regulations – across Iran MarketWe can help you design and execute a tailored strategy at any point in your product’s lifecycle – starting in the planning stages before brand launch all the way past loss of exclusivity. For established brands, applying an integrated multichannel engagement strategy can help you generate greater value and support you during heartland strategy implementation.
  
  

The power of possibilities

  comprehensive expertise can help you confidently interact with regulatory affairs authorities for different therapeutic area and package and present all the information necessary to allow regulatory authorities to make the right decision.
100% of approximately 150 submissions to the FDO have passed technical validation for registering IRC.
50+ DIAF and 1.5 million pages published (all document types, e.g., DIAF /pharmacoeconomic/CTD ).
70% of our regulatory professionals hold advanced degrees, with an average of more than 16 years of experience.

Regulatory Affair
The power of possibilities
EXIRHEALTH ’ comprehensive expertise can help you confidently interact with regulatory affairs authorities for different therapeutic area and package and present all the information necessary to allow regulatory authorities to make the right decision for passing registration prices

• 100% of approximately 35 submissions to the FDO have passed technical validation for registering IRC.
• 50+ DIAF and 30000 pages published (all document types, e.g., DIAF /pharmacoeconomic/CTD ).
• 70% of our regulatory professionals hold advanced degrees, with an average of more than 16 years of experience.

Anticipate what Iran payers want
Payers are pushing for more evidence of value, bringing a new level of scrutiny to formulary and reimbursement decisions. Working together at the earliest stages of your commercial planning, ESS can help you tailor your value proposition and pricing to local and national health plans. Our team of national account managers works with the majority of commercial plans that influence most of the prescriptions written in the Iran. As Iran ministry of health regulatory requirements keep evolving, we’re here to help you increase your chances of regulatory approval.

The power of possibilities
Put our relationships to work for your product. We’ve worked with a majority of all payers – including top managed care organizations, national welfare minister. To learn more, contact our regulatory team.

ExirHealth regulatory team includes over 6 professionals, to help you navigate regulatory requirements throughout your product’s development lifecycle. Comprehensive expertise and capacity to help you gain regulatory approval. On the road to regulatory approval, you invest years and millions of dollars in drug development. Don’t let the complexities of filing across multiple countries delay your launch. With ExirHealth integrated cross-functional expertise we can help increase the probability of successfully registering your products.
The proof of our success ? 87% of ExirHealth Product registration submission to MOH has passed technical validation and registered in IDL in past 5 years.
•    Having sufficient knowledge of drug registration rules & regulations for registration of products
•    Adequately capability of registering new products in the Drug National List
•    Closed relation with MOH to the established and proven commitment & credibility
•    Well knowledge of the drug; raw material and food supplement approval process and registration bureaucracy
•    Submitting registration documents to MOH with a great speed without any delay subsequently pursuing the case, in MOH continuously to receive the needed licenses.

The US FDA has approved Merck & Co's Bridion to reverse the effects of neuromuscular blockade induced by muscle relaxants used during surgery.

ArchiMed, Europe's first independent private equity healthcare specialist, has acquired majority control of Deallus Consulting.